Why the study?
Cardiovascular disease remains the leading cause of death worldwide, prompting the 2019 ESC recommendations to incorporate new evidence on stringent management strategies for patients at high cardiovascular risk.
The review highlights the 2019 ESC guidelines' shift towards more aggressive risk factor modification and the integration of novel cardioprotective therapies for high-risk patients.
May inform updated high-risk prevention strategies; leaves open real-world implementation and outcome data.
Cardiovascular disease is the leading cause of death worldwide. The current recommendations of the European Society of Cardiology (ESC) – 2019 are based on the results of large multicenter clinical trials that have proven the effectiveness of more stringent approaches to the management of patients with high cardiovascular risk. New regimens of drug therapy, the definition of new target values for blood pressure, blood lipid levels and the correction of hyperglycemia, the prevention of thromboembolic complications, are aimed at reducing the risk of cardiovascular events and mortality from cardiovascular diseases. The article discusses recommendations of the European Society of Cardiology – 2019 on the management of patients with chronic coronary disease, with lipid metabolism disorders, and diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Nv et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: